| Assessment Status | Rapid Review Complete |
| HTA ID | 23074 |
| Drug | Talazoparib |
| Brand | Talzenna® |
| Indication | Talazoparib (Talzenna®) in combination with enzalutamide is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. |
| Assessment Process | |
| Rapid review commissioned | 07/12/2023 |
| Rapid review completed | 21/12/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that talazoparib in combination with enzalutamide not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
